Swedish Orphan Biovitrum AB: Gamifant approved in China for the treatment of primary haemophagocytic lymphohistiocytosis

STOCKHOLM, March 18, 2022 /PRNewswire/ -- Sobi today announced that the National Medical Products Administration of China (NMPA) has approved Gamifant (emapalumab) for use in China. The indication

Related Keywords

China ,Sweden ,United States ,Stockholm ,America ,Swedish ,Norbert Oppitz ,Prnewswire Sobi ,Youtube ,Linkedin ,National Medical Products Administration Of China ,Sobi Investor Relations Team ,Head Of International At Sobi ,National Medical Products Administration ,Therapeutic Approaches ,North America ,Middle East ,Sobi Media ,Orphan ,Iovitrum ,Amifant ,Approved ,Treatment ,Primary ,Aemophagocytic ,Ymphohistiocytosis ,